PTC THERAPEUTICS, INC. - 8-K Filing
PTC Therapeutics reported Q1 2026 total revenue of $273 million, including $226 million in product revenue, driven by $125 million in revenue from Sephience, which grew 36% quarter-over-quarter. The company raised its full-year 2026 product revenue guidance to $750–$850 million and total revenue guidance to $1.08–$1.18 billion. Positive interim results from the PIVOT-HD extension study of votoplam and plans to initiate an open-label vatiquinone study in Q3 2026 were also disclosed. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $PTCT